### Distinct genomic signatures and modifiable risk factors underly the 1 comorbidity between major depressive disorder and cardiovascular disease 2

- 3 Jacob Bergstedt<sup>±,\*,1</sup>
- 4 Joëlle A. Pasman<sup>±,2</sup>
- 5 Ziyan Ma<sup>±,2</sup>
- Arvid Harder<sup>2</sup> 6
- 7 Shuyang Yao<sup>2, 12</sup>
- 8 Nadine Parker<sup>3</sup>
- 9 Jorien L. Treur<sup>4</sup>
- 10 Dirk J.A. Smit<sup>4</sup>
- Oleksandr Frei<sup>3</sup> 11
- 12 Alexev Shadrin<sup>3</sup>
- 13 Joeri J. Meijsen<sup>5</sup>
- Qing Shen<sup>1,6,7</sup> 14
- 15 Sara Hägg<sup>2</sup>
- 16 Per Tornvall<sup>8</sup>
- Alfonso Buil<sup>5</sup> 17
- Thomas Werge<sup>5,9,10,11</sup> 18
- Jens Hjerling-Leffler<sup>12</sup> 19
- 20 Thomas D. Als<sup>13</sup>
- Anders D. Børglum<sup>14,15,16</sup> 21
- Cathryn M. Lewis<sup>17,18</sup> 22
- Andrew M. McIntosh<sup>19,20</sup> 23
- Unnur A. Valdimarsdóttir<sup>21,1,22</sup> 24
- Ole A. Andreassen<sup>3,23</sup> 25
- Patrick F. Sullivan<sup>2,24</sup> 26
- Yi Lu<sup>±2</sup> 27
- 28 Fang Fang<sup>±,\*,1</sup>
- 29
- 30 <sup>±</sup>Equal contribution
- 31 \*Corresponding authors
- 32
- 33 <sup>1</sup> Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- 34 <sup>2</sup> Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- 35 <sup>3</sup> NORMENT Centre, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo 36 University Hospital, Oslo, Norway
- 37 <sup>4</sup> Genetic Epidemiology, Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
- 38 <sup>5</sup> Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Mental Health Services Copenhagen, Roskilde, Denmark
- 39 <sup>6</sup>Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, Tongji University School
- 40 of Medicine, Shanghai, China
- 41 <sup>7</sup> Institute for Advanced Study, Tongji University, Shanghai, China
- 42 <sup>8</sup> Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
- 43 <sup>9</sup> The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen, Denmark
- 44 <sup>10</sup>Lundbeck Foundation GeoGenetics Centre, GLOBE Institute, University of Copenhagen, Copenhagen, Denmark
- 45 <sup>11</sup>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 46 Denmark
- 47 <sup>12</sup>Department Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden
- 48 <sup>13</sup>Department of Molecular Medicine (MOMA), Molecular Diagnostic Laboratory, Aarhus University Hospital, Aarhus,
- 49 Denmark NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. <sup>14</sup> Department of Biomedicine, Aarhus University, Aarhus, Denmark 50

- 51 <sup>15</sup> The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark
- 52 <sup>16</sup>Center for Genomics and Personalized Medicine, Aarhus, Denmark
- 53 <sup>17</sup>Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK
- 54 <sup>18</sup>Department of Medical and Molecular Genetics, King's College London, London, UK
- 55 <sup>19</sup> Centre for Clinical Brain Sciences, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
- 56 <sup>20</sup> Centre for Genomics and Experimental Medicine, University of Edinburgh, Edinburgh, UK
- 57 <sup>21</sup>Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
- 58 <sup>22</sup> Department of Epidemiology, Harvard TH Chan School of Public Health, Harvard University, Boston, Massachusetts, USA
- 59 <sup>23</sup> K.G. Jebsen Centre for Neurodevelopmental disorders, University of Oslo and Oslo University Hospital, Oslo, Norway
- 60 <sup>24</sup>Departments of Genetics and Psychiatry, University of North Carolina at Chapel Hill, NC, USA

#### Abstract 62

63 Major depressive disorder (MDD) and cardiovascular disease (CVD) are often comorbid, resulting in

- 64 excess morbidity and mortality. Using genomic data, this study elucidates biological mechanisms, key
- 65 risk factors, and causal pathways underlying their comorbidity. We show that CVDs share a large
- proportion of their genetic risk factors with MDD. Multivariate genome-wide association analysis of 66
- the shared genetic liability between MDD and atherosclerotic CVD (ASCVD) revealed seven novel loci 67
- 68 and distinct patterns of tissue and brain cell-type enrichments, suggesting a role for the thalamus. Part
- 69 of the genetic overlap was explained by shared inflammatory, metabolic, and psychosocial/lifestyle risk
- 70 factors. Finally, we found support for causal effects of genetic liability to MDD on CVD risk, but not
- 71 from most CVDs to MDD, and demonstrated that the causal effects were partly explained by metabolic
- 72 and psychosocial/lifestyle factors. The distinct signature of MDD-ASCVD comorbidity aligns with the
- 73 idea of an immunometabolic sub-type of MDD more strongly associated with CVD than overall MDD.
- 74 In summary, we identify plausible biological mechanisms underlying MDD-CVD comorbidity, as well
- 75 as key modifiable risk factors for prevention of CVD in individuals with MDD.

### Main 76

Major depressive disorder (MDD) and cardiovascular disease (CVD) are highly comorbid<sup>1,2</sup>. Several 77 mechanisms might explain the observed comorbidity<sup>2</sup>. One explanation is that genetic risk factors for 78 79 MDD and CVDs overlap<sup>3,4</sup>. While observed genome-wide genetic correlations between MDD and CVD are modest<sup>2-4</sup>, this may be because local genetic correlations of opposing directions attenuate 80 correlations on the genome-wide level, leading to an underestimation of the genetic overlap<sup>5</sup>. The large 81 82 polygenicity of MDD<sup>6</sup> might also mask subtypes with stronger genetic relationships to CVD.

83

84 The observed MDD-CVD comorbidity could also be due to non-genetic factors<sup>7</sup>. Cardiovascular risk 85 factors like high systolic blood pressure, high body mass index (BMI), high levels of low-density lipoprotein cholesterol, high levels of physical inactivity, presence of type 2 diabetes, and smoking have 86 all been associated with MDD<sup>8-10</sup>. Moreover, accumulating data show that psychosocial/lifestyle 87 factors associated with MDD, like low educational attainment, exposure to childhood maltreatment, 88 loneliness, and atypical sleep patterns, are also important risk factors for CVD<sup>11-14</sup>. 89

90

91 One common mechanism underlying MDD, CVD, as well as their shared risk factors could be chronic 92 inflammation. Atherosclerosis, the accumulation of fibrofatty lesions in the arterial wall, is the main 93 cause of CVD<sup>15</sup>. The build-up of atherosclerotic plaque is a long-term inflammatory process mediated 94 by immune components in crosstalk with arterial wall cells<sup>16</sup>. Many lines of evidence also support a 95 role for inflammation in  $MDD^{17}$ . Excessive or long-term psychosocial stress promote the maturation 96 and release of inflammatory cytokines like interleukin (IL)-6, which activate the central nervous system 97 to produce behaviors related to MDD<sup>18</sup>. Importantly, low-grade inflammation, defined by high C-98 reactive protein levels, has been observed in more than a quarter of patients with depression<sup>19</sup>, 99 suggesting the presence of an inflammatory subtype of MDD<sup>20</sup>, which might be especially strongly 100 associated with CVD.

101

102 The full extent of the genetic overlap between MDD and CVD has not been explored. It remains unknown if the genetic overlap is associated with specific tissues or brain cell-types, or how this overlap 103 relates to shared risk factors such as blood pressure, psychosocial/lifestyle traits, metabolic traits, and 104 inflammation. Moreover, causal effects linking these traits are not fully understood <sup>21-24</sup>. 105

106

107 Here, we dissect the genetic overlap between MDD and CVD (coronary artery disease, peripheral artery 108 disease, heart failure, stroke, and atrial fibrillation) by leveraging state-of-the-art genomic data and 109 methods (Fig. 1). We used newly released summary statistics from a genome-wide association study 110 (GWAS) of MDD involving 290,000 cases<sup>6</sup>, with substantially increased statistical power compared to 111 previous GWASs. First, we assessed the pairwise genetic overlap between MDD and CVD on the genome-wide level, as well as on the level of local partitions of the genome and overlapping causal 112 variants with MiXeR<sup>25</sup> and LAVA<sup>26</sup>. Using these methods, we were able to consider the direction of 113 114 correlation at each locus in the genome, providing a more granular understanding of the genetic overlap 115 between MDD and CVD. Second, we identified genetic variants and genes that contribute to the shared 116 liability between MDD and atherosclerotic CVD (ASCVD; coronary artery disease, peripheral artery 117 disease, heart failure, and stroke) using Genomic Structural Equation Modeling (SEM)<sup>27</sup>. We mapped 118 identified variants to brain cell-types using novel annotations based on single-cell RNA sequencing in post-mortem human brain samples<sup>28</sup>. Third, we assessed shared risk factors explaining the association 119 between MDD and CVD. To do so, we evaluated the polygenic overlap between MDD and well-120 121 established risk factors. We then estimated genetic correlation between MDD and CVD adjusting for 122 risk factors, and the genetic correlation between the shared genetic liability between MDD and ASCVD

- 123 and risk factors. Finally, we used Mendelian Randomization (MR) to investigate putative causal effects
- and assess mediation through shared risk factors for MDD and CVD. In brief, this study leverages recent 124
- 125 large-scale GWAS data and triangulates results from current genomic methods to elucidate etiological

126 pathways underlying the comorbidity between MDD and CVD.



\*: Atherosclerotic Cardiovascular Disease (ASCVD) does not encompass atrial fibrillation.

t: Psychosocial/lifestyle is abbreviated to psychosocial



127

128 Figure 1. Graphical abstract illustrating the study approach. The comorbidity between MDD and CVD 129 is investigated using genetic and causal inference methods, including assessing overlap with and

130 mediation through shared risk factors (metabolic, psychosocial/lifestyle, inflammatory, and blood

- pressure; Supplementary Table 1). The risk factor group psychosocial/lifestyle is abbreviated to
- 131 132 psychosocial. Created with BioRender.com (license agreements VG26BG3VTL, MK26BG46H3).

#### **Results** 133

#### Most genetic risk factors for CVD overlap with MDD 134

135 There were weak to moderate genome-wide genetic correlations between MDD and CVDs, as estimated 136 with linkage disequilibrium score regression (LDSC<sup>29</sup>; Extended Data Fig. 1, Supplementary Table 2). Information on source GWASs for all traits is given in Supplementary Table 1. The strongest 137 138 correlations were noted for peripheral artery disease ( $r_e=0.30$ , SE=0.04,  $P=1\times10^{-13}$ ), heart failure  $(r_{g}=0.29, \text{ SE}=0.03, P=1\times10^{-24})$ , and coronary artery disease  $(r_{g}=0.25, \text{ SE}=0.02, P=9\times10^{-45})$ , while 139 smaller but statistically significant correlations were observed for stroke and atrial fibrillation ( $r_a=0.18$ 140 and  $r_g=0.11$ ,  $P<1\times10^{-7}$ ). ASCVDs showed strong correlations among each other, while atrial fibrillation 141 142 was only moderately genetically correlated to the ASCVDs (Extended Data Fig. 2a, Supplementary 143 Table 2). To aid interpretation of these results, we also analyzed specific MDD symptoms. Poor appetite 144 or overeating was consistently the symptom that showed the strongest genetic correlation to the CVDs 145 (Extended Data Fig. 1a).

146

We then estimated local genetic correlations between MDD and CVDs in each of 2,495 distinct genomic 147

regions used in LAVA<sup>26</sup>. The distribution of local genetic correlations is displayed in Fig. 2a, with 148

149 points exceeding the horizontal line representing partitions with a genome-wide significant correlation

150  $(P_{FDR} < 0.05)$ . We found 54 significant local correlations between MDD and CVDs, 40 of which were

151 for MDD and coronary artery disease. Most significant local correlations were positive (90%), although 152 results were mixed for peripheral artery disease and heart failure, with 50% and 25% of the partitions,

153 respectively, showing negative correlations with MDD (Supplementary Table 4). We also investigated

154 local genetic correlation between MDD and the CVDs in 16 loci in the human leukocyte antigen (HLA)

155 region (Extended Data Fig 1b). Out of 50 assessed local genetic correlations, 8 were significant,

156 indicating that this region is a hotspot of genetic correlation between MDD and CVDs.

157

Next, we investigated genetic overlap on the level of risk variants using MiXeR<sup>25</sup> (Supplementary 158 Tables 5-6). We identified more variants for MDD than for the CVDs, suggesting that MDD is more 159 160 polygenic than CVD. To verify these results, we estimated polygenicity using a complementary Bayesian approach implemented in SBayesS<sup>30</sup>, which showed estimates that were highly correlated 161 162 with those of MiXeR (Extended Data Fig. 2b, Supplementary Table 7).

163

164 Bivariate MiXeR results showed that CVDs shared a large proportion of their causal variants with MDD (from 64% in atrial fibrillation to 92% in heart failure, Fig. 2b) whereas MDD shared only a small 165 proportion of its causal variants with CVDs (<20%). Note that for peripheral artery disease the 166 performance metrics of the model indicate that this finding needs to be interpreted with caution 167 168 (Supplementary Table 6). Both shared genetic variants and local genetic correlations exhibit strong degrees of effect direction concordance (Fig. 2c), suggesting that genetic risk variants for CVDs are 169

170 strongly correlated with a genetic subcomponent of MDD.







172 Figure 2. Genetic overlap between MDD and CVD beyond genome-wide genetic correlation. (a) 173 Volcano plots based on LAVA results showing genomic loci (green dots) with the local genetic 174 correlation between MDD and each of the CVDs (x-axis) and the corresponding *P*-value (y-axis). Loci 175 exceeding the horizontal line are significant at  $P_{\rm FDR}$ <0.05. Multiple testing was performed separately 176 for each trait over all considered loci (b) Venn diagrams based on MiXeR results showing the number 177 of causal variants that are unique to MDD (left circle), unique to CVD (non-overlapping part of right circle), or shared between MDD and CVD (overlapping part of circles). (c) Genetic correlation 178 179 estimated by LDSC (x-axis) against the percentage of MDD variants that are shared with the CVD trait 180 as estimated by MiXeR (first plot), the percentage of CVD variants that are shared with MDD (second 181 plot), and the percentage of CVD variants that are shared with MDD that have concordant effect 182 directions (third plot). The fourth plot shows the percentage of local genetic correlations from LAVA 183 that have concordant effect directions on the y-axis. **a-c** Sample sizes and information for underlying 184 summary statistics GWASs are reported in Supplementary Table 1.

185 MDD=Major Depressive Disorder, PAD=Peripheral Artery Disease, CAD=Coronary Artery Disease, AF=Atrial Fibrillation,

186 HF=Heart Failure

#### Shared genetic liability to MDD and CVD 187

188 To further characterize the genetic overlap, we explicitly modelled the shared liability between MDD 189 and CVD as a higher-order latent factor using Genomic SEM. We excluded atrial fibrillation because it 190 deteriorated the model fit (CFI=0.918, SRMR=0.072) and had the lowest factor loading ( $\beta$ =0.56, SE=0.05), so that the interpretation of the latent factor changed to representing ASCVD. The final 191 192 model had an excellent fit with Comparative Fit Index CFI>0.999 and Standardized Root Mean Squared 193 Residual SRMR=0.021. The factor loading for MDD was  $\beta$ =0.32. The loadings for the ASCVDs ranged from  $\beta$ =0.63 for stroke (SE=0.06, P=4.37×10<sup>-41</sup>) to  $\beta$ =0.85 for heart failure (SE=0.07, P=2.97×10<sup>-56</sup>) 194 195 (loadings standardized on the latent factors are shown in Fig. 3a). For comparison, we also fit a latent 196 factor for the ASCVDs alone (without MDD), which showed similar fit and parameter estimates 197 (CFI>0.999, SRMR=0.013) (Extended Data Fig. 3a). This shows that shared genetic liability to different 198 ASCVDs as well as to ASCVDs and MDD (to a lesser extent) can be explained by a single underlying 199 factor.

200

201 The GWAS on the latent MDD-ASCVD factor resulted in 205 independent genome-wide significant loci (Fig. 3b, independent at  $R^2 < 0.1$  and distance  $\geq 250$ kb, Supplementary Table 8). We did not observe 202 203 genomic inflation, indicating that results were not strongly affected by population stratification (LDSC 204 intercept=1.02). Almost three quarters (74.6%) of the genome-wide statistically significant SNPs 205 showed a high Q heterogeneity, suggesting that their effects were more in line with an independent 206 pathway than a common pathway model (see methods). Most of this heterogeneity was due to MDD, 207 as the GWAS for latent ASCVD without MDD showed fewer genome-wide statistically significant 208 SNPs with a high heterogeneity (30.6%; Extended Data Fig. 3b).

209

For the latent MDD-ASCVD factor, we filtered out variants that showed significant heterogeneity and 210 211 considered only variants where the latent MDD-ASCVD factor was the best model for the follow-up 212 analyses. We retained 72 independent loci underlying the shared genetic liability (Fig. 3b, 213 Supplementary Table 9). The top SNP after filtering was rs11670056 in the ELL gene on chromosome 214 19, which is part of the transcription elongation factor complex and has previously been associated with 215 a range of CVDs, blood traits, BMI, and educational attainment (enrichment in associations with other 216 traits for significant SNPs are shown in Extended Data Fig. 4a). There were 19 top SNPs that were 217 significant eQTLs for one or multiple genes (top 10 are annotated in Fig. 3b, full results are shown in 218 Supplementary Table 10). Besides ELL, multiple genes on chromosome 10 around INA and CNNM2 219 were identified. INA is involved in structural neuron regulation whereas CNNM2 is involved in ion 220 transportation and has previously been associated with psychiatric as well as cardiovascular traits.

221

222 From the latent MDD-ASCVD GWAS summary statistics we extracted seven novel loci that were not 223 among the risk loci in the MDD and ASCVD GWASs that constituted the latent factor (Extended Data 224 Fig. 4b, Supplementary Table 11). The top SNPs in these loci have not been identified in any GWAS

225 recorded in the GWAS catalog before, but four of them have shown suggestive associations (P < 0.05)

- with metabolic traits (rs11065577, rs11606884, rs2838351, and rs500571). 226
- 227

228 Using partitioned LDSC, we observed that the heritability of the latent MDD-ASCVD factor was 229 enriched in genes with expression specific to endothelial and blood vessel tissues, which was also 230 observed for latent ASCVD, but not for MDD (Fig. 3c, Supplementary Table 12). To gain deeper 231 insights into brain-specific mechanisms, we leveraged high-resolution human brain single-nucleus 232 RNAseq data<sup>28</sup> and identified four human brain cell-types that exhibited enriched MDD-ASCVD 233 heritability, including deep layer corticothalamic and 6b cells, midbrain-derived inhibitory neurons,

234 miscellaneous neurons, and vascular cells (Fig. 3d, Supplementary Table 13). Notably, three of the four 235 cell-types were uniquely associated with the latent MDD-ASCVD factor, displaying no enrichment for 236 either latent ASCVD without MDD or MDD only, suggesting that the genetic variance for MDD-ASCVD comorbidity has a distinct functional signature. 237

238

239 To externally validate the MDD-ASCVD phenotype, we computed polygenic risk scores (PRS) based 240 on the summary statistics for the latent MDD-ASCVD factor, as well as for MDD and latent ASCVD, 241 and found them to significantly predict ASCVD and MDD diagnoses in UK Biobank (UKB) (all 242  $P < 2 \times 10^{-13}$ ; Supplementary Tables 14-15; note that source and target samples were overlapping and the 243  $R^2$  values should only be interpreted relative to one another). The PRS for latent ASCVD and the latent 244 MDD-ASCVD factor explained similar amounts of variance in ASCVD (Fig. 3e). This is in line with 245 the MiXeR findings (Fig. 2b), suggesting that most causal variants for ASCVD are shared with MDD. 246 In contrast, as most causal variants for MDD are not shared with ASCVD, the PRS for the latent MDD-247 ASCVD factor explained less than half as much variance in MDD as the MDD PRS.

248

249 Next, we assessed genetic correlations between the latent MDD-ASCVD factor and MDD symptoms. 250 We found that poor appetite or overeating and suicidal thoughts are the symptoms most strongly 251 correlated with MDD-ASCVD. In contrast, poor appetite or overeating is among the least genetically

252 correlated symptoms to MDD (Extended Data Fig. 4c).

253

254 Finally, we estimated genetic correlation of attention deficit and hyperactivity disorder (ADHD), anxiety disorders, post-traumatic stress disorder, bipolar disorder, and schizophrenia, with MDD, 255 256 MDD-ASCVD, and ASCVD. We found that ADHD, anxiety disorder, and PTSD were genetically

correlated with ASCVD (Extended Data Fig. 4d). In addition, PTSD and ADHD showed similar genetic 257

258 correlations for MDD and MDD-ASCVD, which might suggest that the variants that are common to

259 MDD and ASCVD explain most of the genetic correlation between MDD and these disorders.





260

Figure 3. Shared genetic liability factor for MDD-ASCVD. (a) Latent factor model as specified in 261 262 Genomic SEM with the 'observed' variables in rectangles and the latent variables in circles. Factor 263 loadings (standardized on the latent factors) are given in black and variances in blue. Sample sizes for 264 underlying GWAS summary statistics are reported in Supplementary Table 1 (b) Latent MDD-ASCVD 265 factor GWAS results. The x-axis shows genomic position, and the y-axis shows statistical significance as  $-\log_{10}(P)$ . Genome-wide significant SNPs that were filtered out because of significant heterogeneity 266  $Q_{SNP}$  are displayed in grey. The top 10 eQTL genes are displayed with dashed vertical lines indicating 267 their position. (c) Enrichment results in GTEx tissues for the latent MDD-ASCVD factor, with latent 268 ASCVD (without MDD) and MDD-only as comparison. (d) Enrichment results for the latent MDD-269 270 ASCVD factor, latent ASCVD, and MDD-only in brain cell types. (e) Proportion of variance explained 271 in MDD and CVD phenotypes in the UKB (defined using ICD-codes listed in Supplementary Table 14) 272 by each of 3 PRSs for the latent MDD-ASCVD factor, latent ASCVD, or MDD-only. c, d Enrichment 273 is measured using significance testing in a two-sided t-test displayed as  $-\log_{10}(P)$ . Only tissues with a 274 significant association ( $P_{\text{FDR}} < 0.05$ ) are shown. Multiple testing was performed over tested tissues/cell-275 types.

276 MDD=Major Depressive Disorder; MDD-ASCVD=common factor for MDD and ASCVD; ASCVD=common factor for the

277 atherosclerotic cardiovascular diseases

#### 278 Polygenic overlap between MDD and risk factors

279 Next, we aimed to identify risk factors that contribute to the genetic and phenotypic association between 280 MDD and CVD. First, we assessed the genome-wide genetic correlations between MDD and risk 281 factors. Confirming previous findings, we observed strong to moderate genetic correlations of MDD with psychosocial/lifestyle factors, such as loneliness ( $r_g=0.68$ , SE=0.02), childhood maltreatment 282 283  $(r_g=0.55, SE=0.02)$ , and exercise  $(r_g=-0.33, SE=0.02)$  (Fig. 5, Extended Data Fig. 6). Among metabolic 284 factors, MDD showed the strongest genetic correlation with type II diabetes ( $r_g=0.19$ , SE=0.018), followed by levels of high-density lipoprotein cholesterol ( $r_{e}$ =-0.14, SE=0.01) and triglycerides 285 286  $(r_r=0.18, \text{SE}=0.02)$ . MDD showed weak but statistically significant genetic correlations with other 287 metabolic factors (i.e., BMI, non-high-density lipoprotein, low-density lipoprotein, and total 288 cholesterol) ( $r_e < 0.15$ ). We observed significant genetic correlations for MDD with the inflammatory 289 markers IL-6 ( $r_g$ =0.22, SE=0.06) and C-reactive protein ( $r_g$ =0.15, SE=0.02). We did not observe genetic 290 correlation of MDD with blood pressure traits. As a comparison, for CVDs, the largest genetic 291 correlations were found between heart failure and BMI ( $r_e=0.55$ , SE=0.03) and type II diabetes ( $r_e=0.49$ , 292 SE=0.03) (Extended Data Fig. 5, Supplementary Table 2). Results for MDD symptoms largely followed the pattern of MDD diagnosis, although changed appetite showed stronger genetic correlations with 293 294 metabolic factors than did MDD diagnosis (Extended Data Fig. 6, Supplementary Table 3).

295

296 Causal variant and local genetic correlation analysis revealed several distinct patterns of polygenic 297 overlap between MDD and risk factors. We found that psychosocial/lifestyle factors, childhood 298 maltreatment, and BMI showed similar levels of polygenicity to MDD (Extended Data Fig. 2b, 299 Supplementary Tables 5 and 7). In addition, they exhibited a large degree of shared variants and many 300 local genetic correlations with MDD (Fig. 4a, Extended Data Fig. 7, Supplementary Tables 4 and 6). 301 Out of these factors, loneliness and childhood maltreatment also showed high levels of effect direction 302 concordance (93% and 73% of shared causal variants and 85% and 75% of significant local genetic 303 correlations for loneliness and childhood maltreatment were in the same direction; Fig. 4b, correlation 304 coefficients are shown in Supplementary Tables 4 and 6). Combined with high polygenicity, such 305 concordance translates to large genome-wide genetic correlations. In contrast, educational attainment, 306 smoking, exercise, physical activity, BMI, and sleep duration had similar levels of polygenicity and a 307 large degree of polygenic overlap with MDD, but low effect direction concordance, suggesting that 308 genome-wide genetic correlations underestimate the polygenic overlap with MDD for these traits. 309

310 Genetic factors for blood pressure traits showed unique patterns of polygenic overlap in that they were 311 polygenic (>5,000 causal variants; Extended Data Fig. 2b) but did not overlap strongly with genetic risk 312 factors for MDD (<0.30 of risk variants overlapping; Fig. 4a). Moreover, risk variants that did overlap 313 showed low degree of effect direction concordance (48%-57% of shared variants in the same direction; 314 Fig. 4b). We observed 97 significant local genetic correlations for the three blood pressure traits, 60% 315 of which were positive. These findings suggest that MDD and blood pressure share variants that exhibit 316 both positive and negative correlations, which are cancelled out in the genome-wide estimate.

317

318 Type II diabetes, lipid traits, and C-reactive protein showed low polygenicity (<2,500 causal risk 319 variants). Total cholesterol, non-high-density lipoprotein, and low-density lipoprotein did not share the 320 majority of their risk variants with MDD, and shared variants showed low degrees of effect direction 321 concordance. However, like the CVDs, type II diabetes, triglyceride levels, and C-reactive protein levels

322 shared most of their risk variants with MDD, and these variants showed high degrees of concordance





326 Figure 4. Local and causal-variant level genetic correlations between MDD and risk factors. The legend is shared among all panels. (a) Venn diagrams based on MiXeR results showing the number of causal 327 328 variants that are unique to MDD (left circle), the risk factor (non-overlapping part of right circle) or 329 shared between MDD and the risk factor (overlapping part of circles). (b) Genome-wide genetic 330 correlation estimated by LDSC (rg, x-axis) against the percentage of MDD causal variants that are shared with the risk factor as estimated by MiXeR (top left), the percentage of risk factor causal variants 331 332 that are shared with MDD (top right), the percentage of risk factor causal variants that are shared with 333 MDD that have concordant effect directions (bottom left). The bottom right plot shows the percentage

- 334 of local genetic correlations from LAVA that have concordant effect directions on the y-axis.
- 335 Cardiovascular traits are also shown for comparison. a, b Standard errors for MiXeR, LAVA, and LDSC
- 336 results are reported in Supplementary Tables 2-6. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1. Note that IL6 was excluded from MiXeR results because it failed 337
- 338 performance checks (see methods).
- 339 Psychosocial=Psychosocial/Lifestyle; PAD=Peripheral Artery Disease, CAD=Coronary Artery Disease, AF=Atrial
- 340 Fibrillation, HF=Heart Failure, DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure;
- 341 Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes;
- 342 TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol;
- 343 LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein;

### 344 Risk factors explain part of the genetic correlation between MDD and CVD

- 345 To assess the degree to which risk factors explain the genetic overlap between MDD and CVD, we 346 estimated genetic correlations adjusted for risk factors (individually or as a group) using Genomic SEM 347 (Fig. 5a; results per individual risk factor are shown in Extended Data Fig. 8 and Supplementary Table Table 16). The largest reduction in point estimate was observed for the genetic correlation between 348 349 MDD and peripheral artery disease after adjustment for the group of psychosocial/lifestyle factors, indicating that these risk factors explain much of the genetic correlation between MDD and peripheral 350 351 artery disease. Similarly, the genetic correlation between MDD and coronary artery disease, as well as 352 the latent CVD factor, were attenuated after adjusting for psychosocial/lifestyle factors. The reduction 353 was mainly driven by loneliness (Extended Data Fig. 8). Genetic correlations of MDD with peripheral 354 artery disease and stroke were no longer significant after adjusting for psychosocial/lifestyle factors. 355 We also observed some attenuation in the genetic correlation between MDD and CVD after adjusting 356 for childhood maltreatment, metabolic factors, or inflammatory markers, although confidence intervals 357 overlapped.
- 358

359 Next, we specified the risk factors as mediators instead of covariates in the Genomic SEM model and 360 compared the path estimates from MDD to CVD. Observing attenuation in the association between 361 MDD and CVD when a risk factor is modelled as a mediator rather than a covariate supports the interpretation that the risk factor mediates some of the link between MDD and CVD. For all 362 363 psychosocial/lifestyle factors together, the inflammation traits, and for type II diabetes, the 95% 364 confidence intervals did not overlap between the mediator and covariate models, suggesting that these 365 risk factors are mediating part of the link between MDD and CVD (Supplementary Table 17).

366

Finally, we estimated genetic correlations between the risk factors and the latent MDD-ASCVD factor 367 (Fig. 5b) and found that the latent MDD-ASCVD factor was substantially more genetically correlated 368 369 with blood pressure traits, C-reactive protein levels, and metabolic factors than MDD only, suggesting that these factors characterize the genetic liability to MDD-ASCVD rather than to MDD alone. 370

- 371
- 372





- 373
- 374

375 Figure 5. Genome-wide correlations between MDD and risk factors. (a) Genetic correlation between 376 MDD and CVD before and after adjustment for groups of risk factors (color coded). (b) Comparison of 377 genetic correlation between MDD (dark green) and the latent CVD-ASMDD factor (lilac) and 378 individual risk factors. a, b Points and error bars represent correlations and 95% CIs. Sample sizes for 379 GWAS summary statistics are reported in Supplementary Table 1.

380 Psychosocial=Psychosocial/Lifestyle; MDD=Major Depressive Disorder; AF=Atrial Fibrillation; CAD=Coronary Artery 381 Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; 382 PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; 383 T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; 384 TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein

#### 385 Causal pathways linking MDD and CVD

386 We investigated putatively causal relationships between MDD and CVD using two-sample MR. Results 387 from the inverse variance-weighted (IVW) estimator are presented in Fig. 6a-c (full results including sensitivity analyses Supplementary Table 18). Instruments were Steiger filtered, i.e., SNPs explaining 388 389 significantly more variance in the outcome than the exposure were excluded. The results provide 390 support for a causal effect of MDD liability on all CVDs, with the strongest effects observed for 391 coronary and peripheral artery disease. There was no statistically significant pleiotropy for the CVD 392 outcomes, and the results were consistent across weighted median, mode, and Egger sensitivity 393 analyses, providing support for the IVW estimates. Concerning risk factors, we observed no support for 394 a causal effect of MDD liability on levels of blood pressure, physical activity, sleep duration, or IL6. 395 However, increased liability to MDD was associated with increased risk of loneliness, smoking, type II 396 diabetes, and levels of C-reactive protein (Fig. 6a). The results were again consistent across sensitivity 397 analyses. There was statistically significant pleiotropy between MDD and triglycerides, rendering this 398 effect uninterpretable. The average instrument strength of MDD was F=33. Heterogeneity across 399 instruments was statistically significant for most outcomes, suggesting variable effects (Supplementary 400 Table 18).

402 We also investigated the potential causal effect in the other direction with genetic instruments to CVDs 403 and risk factors as exposures and MDD as outcome (Fig. 6b). We provide evidence for a statistically 404 significant causal effect of stroke, loneliness, smoking, exercise, educational attainment, childhood maltreatment, high-density lipoprotein, and BMI on MDD risk (Fig. 6b), which was robust across the 405 sensitivity analyses. No robust effects were observed for other CVDs, blood pressure, other metabolic 406 407 traits, or inflammatory markers.

408

409 When using genetic instruments for the latent MDD-ASCVD factor to predict the risk factors, 410 statistically significant effects were observed for pulse pressure and type II diabetes (Extended Data 411 Fig. 9c). There was statistically significant pleiotropy only for systolic blood pressure. There were small 412 effects on BMI, childhood maltreatment, educational attainment, high-density lipoprotein, exercise, 413 loneliness, and smoking, but these were less robust across sensitivity analyses (Supplementary Table 414 18). For most outcomes, there was statistically significant instrument heterogeneity.

415

416 We extended univariable results with multivariable MR to assess if there was support for causal effects 417 of MDD on CVD explained by the risk factors. We included only risk factors that were statistically 418 significantly predicted by MDD in the univariable MR analysis. Fig. 6c shows that, as in the Genomic 419 SEM analyses, the effect of MDD on CVD was attenuated after adjusting for groups of risk factors, 420 although confidence intervals were wide. Results for individual risk factors are shown in Extended Data 421 Fig. 10 and Supplementary Table 19. The effect of MDD liability on peripheral artery disease, heart 422 failure, stroke, and atrial fibrillation risk was no longer statistically significant after adjusting for the groups of metabolic or psychosocial/lifestyle factors, although the confidence intervals overlapped with 423 424 those from the unadjusted estimates. Likewise, the effect of MDD on atrial fibrillation was no longer 425 statistically significant after adjusting for childhood maltreatment. In Fig. 6d we show a schematic 426 overview of results from all MR analyses.

427

428 To investigate possible bias due to sample overlap, we repeated the main IVW analyses using MDD summary statistics based on GWAS excluding the UKB sample (the main source of overlap). We 429 430 observed small differences in the estimates, but the interpretation remained the same for all results 431 (Extended Data Fig. 9a-b, Supplementary Table 20). Furthermore, we repeated the analyses using Latent Heritable Confounder (LHC) MR, which is robust to sample overlap<sup>31</sup>. The results pattern was 432 433 similar, although the point estimates were slightly attenuated for CVD risk (e.g., no longer statistically significant for heart failure and atrial fibrillation) and became stronger for most other traits (Extended 434 435 Data Fig. 9c). We conclude that although sample overlap impacted the point estimates, the interpretation 436 of results remained similar.



438

Figure 6. Results from univariable and multivariable MR (IVW estimates). (a) Effect of liability to 439 MDD (exposure) on CVD and risk factors (outcomes). (b) Effects in the opposite direction with MDD 440 441 as outcome and CVD and risk factors as exposures. (c) Effects of MDD on CVD while adjusting for 442 groups of risk factors in multivariable MR. (d) Schematic overview of levels of evidence for causal 443 effects, with solid lines indicating convincing evidence (consistent across sensitivity analyses) for such 444 effects, and dashed lines indicating evidence for some of the relationships tested within the trait categories. The arrows from the risk factors to the association between MDD and the CVDs indicate 445 446 that the combined risk factors attenuated the association so that it was no longer statistically significant. 447 a-d Points and error bars represent regression coefficients and 95% CIs. Sample sizes for GWAS 448 summary statistics are reported in Supplementary Table 1. The term beta refers to the log odds ratio.

449 \* Indicates that the observed statistically significant association suffered from pleiotropy; possible 450 causal effect should not be interpreted.

451 Psychosocial=Psychosocial/Lifestyle; MDD=Major Depressive Disorder; MDD-ASCVD=common factor for CVD and MDD 452 and ASCVD; PAD=Peripheral Artery Disease; HF=Heart Failure; STR=Stroke; CAD=Coronary Artery Disease; AF=Atrial

453 Fibrillation; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment;

454 Phys. Act.=Physical activity; Child. Mal.= Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-455 Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein;

IL6=Interleukin-6; CRP=C-Reactive Protein; MR=Mendelian randomization IVW=Inverse Variance Weighted.

456

#### 457 Discussion

458 Here, we showed that genetic risk factors for CVD overlap strongly with MDD. We modeled the shared 459 genetic liability between MDD and ASCVD as a latent factor and showed that, distinct from MDD 460 alone, it is associated with gene expression specific to thalamic and vascular cell-types in the brain and 461 is genetically correlated with immunometabolic factors and blood pressure. Further, we showed that the 462 association between MDD and CVD is partly explained by modifiable risk factors and provide evidence that it is likely causal in nature. 463

464

465 In line with previous results<sup>32–35</sup> we found weak to moderate genome-wide genetic correlations between MDD and CVDs. Analysis on the level of shared risk variants showed that MDD was substantially 466 more polygenic than the CVD traits and that most risk variants for CVD were in fact shared with MDD 467 468 and had concordant effect directions. In addition, we found many positive local genetic correlations 469 between MDD and CVD, especially for coronary artery disease although that might reflect the fact that 470 the coronary artery disease GWAS have substantially larger effect sample size than the GWASs of the 471 other CVDs. Interestingly, we found that the HLA region was a hotspot for local genetic correlation 472 between MDD and CVDs. These findings suggest that genetic overlap between MDD and CVD is 473 underestimated in genome-wide correlation analyses.

474

475 We modelled the shared liability between MDD and ASCVD as a latent factor and performed a GWAS 476 on the factor. Atrial fibrillation deteriorated the fit of the latent factor and it was therefore excluded. 477 This was in line with results that showed that atrial fibrillation was substantially less genetically 478 correlated with the ASCVDs than they were with each other. Combined, these results suggest that atrial 479 fibrillation and ASCVDs have partly distinct sources of genetic variation. We identified many loci for 480 MDD-ASCVD, some of which were uniquely associated with the shared liability and not with the constituent traits. We found that heritability for the MDD-ASCVD latent factor was enriched for genes 481 482 specifically expressed in vascular braincells, deep layer corticothalamic 6b (projecting to the thalamus), 483 and midbrain-derived inhibitory neurons (predominantly located in the thalamus). This cell-type 484 enrichment signature was not found for MDD or ASCVD alone, suggesting that a distinct mechanism 485 involving thalamic circuits underlies the shared liability to MDD-ASCVD. Altered thalamic function has indeed been implicated previously in CVD<sup>36–38</sup> and MDD<sup>39,40</sup>, and white matter integrity in thalamic 486 radiations show associations with aortic area and myocardial wall thickness, suggesting that it has a role 487 488 in the 'heart-brain' connection<sup>41</sup>.

489

490 MDD showed a high degree of genetic overlap with risk factors. We showed that MDD was 491 substantially more polygenic than blood pressure traits, lipid traits, and C-reactive protein. In contrast, psychosocial/lifestyle traits were equally polygenic to MDD and showed a large degree of overlap with 492 493 MDD. Interestingly, the local and variant-level analysis indicated that blood pressure traits shared a 494 substantial proportion of their risk variants with MDD (in line with a previous report<sup>42</sup>), which was 495 masked at the genome-wide level due to their opposing effect directions. Similarly, BMI and lipid traits 496 showed discordant effect directions to MDD in overlapping risk variants as well as opposite directions 497 in local genetic correlations. Finally, C-reactive protein shared almost three quarters of its risk variants 498 with MDD, most of which were in the positive direction, indicating a genetic relationship between C-499 reactive protein and MDD that was masked by the large polygenicity of MDD. Overall, these findings

500 refine our understanding of the polygenic overlap between MDD and risk factors shared between MDD 501 and CVD, and indicate that it is stronger and more complex than has previously been reported.

502

503 We estimated genome-wide genetic correlations between MDD and CVD adjusting for risk factors and

found that psychosocial/lifestyle factors explain a substantial part of the genetic correlation between 504

505 MDD and CVD and highlight loneliness as an important factor in the relationship between MDD and

506 CVD. 507

508 We found that, compared to MDD, the latent MDD-ASCVD factor was characterized by genetic 509 correlations with immunometabolic factors and blood pressure, suggesting that the shared genetic 510 liability to MDD and ASCVD is associated with an immunometabolic subtype of depression. The 511 existence of an immunometabolic subtype of depression has been proposed previously, based on a long 512 line of evidence of oxidative stress and neuroendocrine and inflammatory dysregulation in MDD, that 513 are preferentially associated with atypical symptoms of MDD (e.g., weight gain and oversleeping)<sup>43</sup>. 514 Indeed, we find that poor appetite or overeating is the MDD symptom with the consistently greatest 515 genetic correlations to the CVDs, and it is among the most genetically correlated with MDD-ASCVD, 516 while it is among the least correlated symptoms to MDD, although confidence intervals were too wide 517 to be conclusive. We did not find large genetic correlations between sleep duration measured using an accelerometer over one week and the MDD-ASCVD factor. However, statistically significant variants 518 519 for the MDD-ASCVD factor were strongly enriched in statistically significant variants for self-reported short sleep duration (<6 hours per night)<sup>44</sup> suggesting that short sleep duration is more related to MDD-520 ASCVD comorbidity than overall sleep duration. 521

522

523 Mental disorders that are highly comorbid with MDD, such as psychotic disorders, anxiety disorders 524 and PTSD, have also been shown to be associated with CVD<sup>45</sup>. We find that ADHD, anxiety disorders 525 and PTSD show genetic correlations with ASCVD and MDD-ASCVD. For ADHD and PTSD, the 526 genetic correlation was similar between MDD and MDD-ASCVD. Future work should estimate latent 527 factors representing shared and distinct sources of genetic covariance between MDD, ADHD, anxiety 528 disorders, and PTSD and investigate how those factors relate to ASCVD.

529

530 We found robust support for the likelihood of causal effects of MDD on CVD. Previous two-sample 531 MR studies have observed associations between genetic liability to MDD and risk of coronary artery disease but results for risk of heart failure have been inconsistent<sup>32,33,46,47</sup>. Another study found an effect 532 533 of genetic liability to MDD on risk of stroke<sup>48</sup>. Using more recent GWAS data, we confirmed an effect 534 of genetic liability to MDD on coronary artery disease and stroke and found robust associations for 535 heart failure and peripheral artery disease.

536

537 Except for stroke, we found limited evidence for a causal effect of CVDs on MDD, which is contrary to literature suggesting that such effects exist<sup>24</sup>. The MDD sample is mainly based on large volunteer-538 539 based studies that might select against individuals with CVD. Indeed, participants in the UKB study are healthier than the general population<sup>49</sup>. In addition, interpretation of the MR estimate in this case is 540 541 complicated by the fact that CVD is a time-varying exposure with late age-of-onset<sup>50</sup>. However, we do 542 find that genetic instruments capture the well-established association between stroke and subsequent 543 MDD<sup>51</sup>. Therefore, the findings in our study offer some indication that the association between CVDs 544 and subsequent MDD might have been overestimated in previous studies, possibly due to reverse 545 causation, surveillance bias, or unmeasured confounding.

547 We observed effects of genetic liability to MDD on most of the risk factors. We did not observe 548 associations between genetic liability to MDD and blood pressure traits, although the presence of 549 correlated and anti-correlated genetic components complicates interpretation. Indeed, using genetic instruments for the latent MDD-ASCVD factor, we did observe strong associations for pulse pressure. 550 Previous MR studies of the association of C-reactive protein and IL-6 levels with MDD risk have also 551 shown inconsistent results<sup>52,53</sup>. We did not find an effect of genetic instruments for inflammatory 552 markers on MDD. However, we did find associations between genetic liability to MDD and increased 553 554 C-reactive protein levels, lipid levels, and type II diabetes, offering evidence that MDD might lead to long-term dysregulated immunometabolic pathways<sup>43</sup>. Likewise, in line with previous evidence<sup>54</sup>, we 555 556 provided support for a causal effect of liability to MDD on smoking, which, in turn, can lead to 557 inflammation. These results are in line with results based on genetic covariance estimated from all genetic variants that tentatively supported a mediating role for C-reactive protein and IL6 levels in the 558 559 association between MDD and ASCVD.

560

561 Analyzing risk factors explaining the effect of genetic liability to MDD on CVDs, we observed that only the association between genetic liability to MDD and coronary artery disease remained statistically 562 563 significant after adjusting for psychosocial/lifestyle or metabolic covariates in a multivariable MR 564 analysis. In addition, we found that smoking status attenuates the association between genetic liability 565 to MDD and peripheral artery disease, for which smoking is a particularly strong risk factor<sup>55</sup>. Interestingly, we find that loneliness is an equally important factor explaining the relationship between 566 MDD and peripheral artery disease, as well as heart failure, which is in line with the results from the 567 adjusted genome-wide genetic correlation analysis discussed above. This emphasizes the need for 568 569 interventions and preventive policies for reducing loneliness in the population, which has a further 570 increased prevalence during the COVID-19 pandemic and has been described as a pandemic itself<sup>56,57</sup>. 571

572 For most CVDs, no risk factor group could fully explain the genetic association between MDD and the 573 CVD. This suggests that there are other mechanisms at work as well, which are not captured by the 574 genetic data used in the study. For instance, GWAS measure lifetime genetic risk (up to the point of the 575 maximum age in the sample) and cannot capture dynamic processes of cumulative and interactive risk. 576 Relatedly, the statistical genetic tools we employed cannot formally distinguish between mediation and 577 covariation pathways. Future studies should triangulate our findings using longitudinal observational 578 and experimental data. Follow-up studies could also investigate the out-of-sample predictive power and 579 clinical usefulness of polygenic risk scores for the shared liability to MDD-ASCVD, and evaluate their 580 ability to identify individuals at risk for immunometabolic depression, as we could not investigate this due to sample overlap in the present study. Another limitation is that the bivariate MiXeR model was 581 not able accurately estimate the polygenic overlap between MDD and IL6. The likely reason the MiXeR 582 model failed in this case is because the two traits have very different genetic architectures with MDD 583 584 being highly polygenic and IL6 being the least polygenic of the traits in the study, combined with the 585 low sample size of the IL6 GWAS. In addition, to assess generalizability, these findings should be replicated with data from different ancestry sources. The lack of large genetic datasets from non-586 587 European populations is a crucial limitation that is widely acknowledged and yet difficult to circumvent. 588 Observational studies have shown that MDD and CVDs could demonstrate different associations depending on ancestry<sup>58,59</sup>, and more genetic and non-genetic research is needed to understand such 589 590 differences.

591

592 To our knowledge, this is the first study moving beyond bivariate genetic overlap to investigate the 593 latent genetic liability shared between MDD and ASCVD. Our triangulation of genome-wide, local, 594 and variant-level methods provides compelling evidence that MDD and CVD, and their shared risk

595 factors are more strongly overlapping genetically than has previously been reported. Similarly, using 596 genome-wide, variant-level, and genetic instrument methods we show how shared risk factors explain the likely causal association between MDD and CVD. For both MDD and CVDs, we have used updated 597 GWAS summary statistics, with an up to 3-fold increase in sample size compared to previous reports 598 599 32–35

600

601 This study dissected the architecture of polygenic overlap between MDD and CVD, and their shared 602 risk factors to elucidate mechanisms linking these comorbid diseases. Our findings suggest that the 603 shared genetic liability to MDD and ASCVD has a distinct genomic signature compared to MDD or 604 any CVD separately. Moreover, the shared genetic liability shows stronger genetic correlations with immunometabolic risk factors than MDD alone, in line with the idea of an inflammatory<sup>60</sup> or 605 immunometabolic<sup>43</sup> subtype of MDD especially associated with atherosclerotic CVDs, highlighting the 606 607 role of inflammation in MDD-ASCVD comorbidity. Indeed, we found that the HLA region is a hotspot 608 of local genetic correlation between MDD and the CVD traits, that genetic liability to MDD is 609 associated with C-reactive protein levels, and tentative support that inflammatory markers mediate some of the link between MDD and ASCVD. We highlight loneliness and smoking as important targets 610 611 for intervention to reduce the risk of MDD and CVD, as well as CVD in individuals with MDD. 612 Building on this work, tools can be developed to identify individuals at risk for developing 613 immunometabolic depression (e.g., using blood tests of high-density lipoprotein and C-reactive protein

levels) and target them for cholesterol-lowering or anti-inflammatory medical interventions. 614

## 615

#### **Methods** 616

#### 617 **Data sources**

All data sources were summary statistics from the largest and most recent GWAS to date (see 618 619 Supplementary Table 1). The MDD symptoms GWAS have not been published, although they have been used in other publications<sup>61</sup>. The symptom GWASs were based on Patient Health Questionnaire 620 (PHO-9) items measured in the UKB, that captures most, but not all, core symptoms of MDD, and were 621 published online<sup>62</sup>. The disease trait GWASs were mostly based on electronic health record diagnoses. 622 623 The physical activity and sleep duration traits were measured in the UKB using an accelerometer over 624 a one-week period<sup>63</sup>.

625

626 The statistics pipeline summary were cleaned using the cleansumstats (https://github.com/BioPsyk/cleansumstats). SNPs were aligned and harmonized against reference data. 627 628 Analyses were conducted on the TSD cluster, maintained by the University of Oslo, using singularity 629 containers. Containers are packaged applications with their environmental dependencies that are used 630 to standardize analyses across different sites, ensuring correct software versions and parameters<sup>64</sup>. All GWAS studies were ethically approved and were conducted in compliance with ethical guidelines. 631 632 Ethics approval for the UK-Biobank study was given by the North West Centre for Research Ethics Committee (11/NW/0382). The work described here was approved by UK-Biobank under application 633 number 22224. 634

#### **Genetic overlap** 635

636 Genome-wide genetic correlation

637 To assess shared liability between MDD, CVD, MDD symptoms, and risk factors, we estimated genetic 638 overlap on a genome-wide, polygenic, and local level. First, for the genome-wide level, we estimated 639 genetic correlation between each of the traits using LD score regression (LDSC<sup>29</sup>). We excluded the human leukocyte antigen (HLA) region from the main analysis because its complex LD structure can 640 bias both heritability and genetic correlation results<sup>65</sup>. However, a sensitivity analysis including the HLA 641 642 region showed very similar results to the main analysis (not shown). Note that LDSC performs well in

- the presence of sample overlap. 643
- 644 Local genetic correlation

We used Local Analysis of (co)Variant Association (LAVA<sup>26</sup>) to assess genetic correlation in regions 645 of the genome. We assessed local genetic correlation in 2,495 genomic regions that cover the autosomes 646 647 and have been defined to minimize LD between the regions, while simultaneously keeping the regions approximately equal in size. These regions are provided with the LAVA software package. We only 648 649 considered local genetic correlation in loci where both traits showed marginally significant heritability 650 (P < 0.05). For these loci, we adjusted local genetic correlation *P*-values for multiple testing using the Benjamini-Hochberg method. This adjustment was done separately for all pairs of traits considered. To 651 652 match the results from LDSC and MiXeR, we excluded the HLA region from the main analyses. For 653 local genetic correlation between MDD and the CVD traits, we performed an additional analysis in the 654 HLA region.

655 Polygenic overlap

To investigate polygenic overlap beyond genetic correlation, we used MiXeR v1.3<sup>25</sup> to assess the 656 657 number of shared and distinct non-zero genetic variants between MDD and another trait required to

explain at least 90% of heritability in the two traits, referred to as 'causal' variants. Because it assesses 658 overlap regardless of the effect direction of each variant, it gives a more adequate picture of localized 659 correlations that could cancel each other out when estimating the genome-wide genetic correlation. We 660 excluded the HLA region, following the software recommendations<sup>25</sup>. A sensitivity analysis of genetic 661 overlap between MDD and the CVD traits including the HLA region showed very similar results to the 662 main analysis (not shown). To assess stability of point estimates and estimate their standard deviations, 663 664 we fitted the MiXeR model 20 different times for 2 million randomly selected SNPs with minor allele 665 frequency of at least 5%. The number of 20 runs follows recommendations published previously<sup>66</sup>. The averaged results were then plotted in Venn diagrams to visualize the polygenic overlap. The MiXeR 666 667 model was evaluated for each trait using by 1) comparing the AIC of the univariate MiXeR model with the LDSC model, which does not include a parameter to directly estimate polygenicity (Supplementary 668 Table 5); 2) comparing the AIC of the bivariate MiXeR model with the AIC of the model with the least 669 possible amount of polygenic overlap required to explain observed genetic correlation; 3) comparing 670 671 the AIC of the bivariate MiXeR model with the AIC of the model with maximum amount of polygenic 672 overlap (in such a model, all risk variants of the least polygenic trait are also risk variants of the other trait), and finally 4); evaluating the stability of the point estimates over the 20 runs (Supplementary 673 674 Table 6). These metrics have been described in detail previously<sup>66</sup>. Except for the univariate test, the 675 MiXeR model failed these checks for IL6, which was therefore excluded from the results. The MiXeR 676 model performed poorly for the IL6 likely because it is a trait with low polygenicity and was measured 677 in a relatively small sample (Extended Data Fig. 2, Supplementary Table 1).

678

679 To complement the univariate polygenicity analysis in MiXeR, we estimated polygenicity in a Bayesian

680 model implemented in SBayesS<sup>30</sup>. We used a 15,000 sample MCMC chain with a 5,000-sample burnin. The SBayesS methods did not converge for peripheral artery disease, possibly due to lower number 681

of cases in the GWAS. 682

#### Shared liability to MDD and ASCVD 683

To move beyond bivariate association to multivariate overlap, we conducted factor analysis on MDD 684 and the CVDs using Genomic SEM<sup>27</sup> to assess if genetic latent factors could explain the genetic 685 covariance between the traits. Genomic SEM uses LDSC to estimate the genetic covariance matrix and 686 uses that in a SEM framework to identify multivariate relationships in the data. A Comparative Fit Index 687 CFI>.90, Standardized Root Mean Square Residual SRMR<.03, and standardized factor loadings  $\beta$ >0.3 688 were set as criteria for acceptable model fit. The best model fit was found for a factor with coronary 689 artery disease, peripheral artery disease, heart failure, and stroke as indicators, which we interpret as a 690 691 genetic factor for ASCVD. To model a genetic factor for shared liability to MDD and ASCVD, we 692 defined a higher-order factor with this ASCVD factor plus MDD as indicators. The standardized loading 693 of the first indicator (coronary artery disease) was set to 1. The residual variance of the ASCVD factor 694 was forced to be 0, so that all variance was forced into the MDD-ASCVD factor. For comparison, we 695 also estimated a common factor model for ASCVD without MDD, which is visualized in Extended Data 696 Fig. 3a.

697

698 Subsequently, we conducted a summary statistics-based GWAS on the MDD-ASCVD second-order 699 latent factor to identify variants associated with this latent liability. We used the package-default 700 diagonally weighted least squares estimator (DWLS). To derive genome-wide significant independent 701 loci we used the plink clumping procedure as implemented in FUMA<sup>67</sup>, with R=0.6 and distance=250 702 kb, and reference data from 1000 genomes. To assess the heterogeneity of the SNP effects, we also fit

- 703 an independent pathway model for each SNP, where each indicator was regressed on the SNP directly
- instead of forcing the effect through the latent factor. We compare the common pathway  $\chi^{2,com}_{SNP}$  to the 704

medRxiv preprint doi: https://doi.org/10.1101/2023.09.01.23294931; this version posted January 29, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

independent pathway  $\chi_{\text{SNP}}^{2,\text{ind}}$  to derive  $Q_{\text{SNP}}$ . For our follow-up analyses, we filtered out all SNPs that had effects that were more consistent with an independent pathway model at  $P_{Q_{\text{SNP}}} < 0.05$ . This stringent procedure filters out SNPs with heterogenous effects on MDD and the ASCVD factor. This way, variants are excluded that should be considered risk variants for MDD or CVDs separately rather than risk variants for MDD-ASCVD.

710

711 Using FUMA, we checked if genome-wide significant SNPs for the MDD-ASCVD factor were 712 enriched in genome-wide significant SNPs for traits in the GWAS-catalog. Then, to define unique loci, 713 we overlaid the independent genomic risk loci (now clumped at R<sup>2</sup>=0.1 and 3000 kb window) for MDD-714 ASCVD with the risk loci for the constituent traits (MDD, peripheral artery disease, coronary artery 715 disease, heart failure, and stroke). We used the 'intersect' function in bedtools to see if the risk regions 716 were overlapping. If they were independent (according to the clump criteria) they were regarded as 717 novel loci. We also identified genes whose regulation is significantly impacted by the top significant 718 SNPs to interpret the biological implications of our findings. For this, we use eQTL estimates from 719 FUMA based on PsychENCODE reference data<sup>68</sup>. Using the same procedures (though without filtering 720 out heterogeneous SNPs) we conducted a GWAS for the the ASCVD genetic factor.

721

722 To externally validate the latent MDD-ASCVD GWAS results, we computed PRS using LDpred2 723 (automatic mode with HapMap3 reference data). We compared the MDD-ASCVD PRS with a PRS 724 based on MDD only, and with a PRS based on latent CVD without MDD. As a target sample we used 725 the UKB. Summary statistics for ASCVD traits excluding the UKB were unavailable, and we chose to 726 leave the UKB in for all traits. Sample overlap is likely to lead to overfitting, resulting in an inflation 727 of explained variance. However, this is less of a concern when comparing PRS among themselves. 728 rather than assessing absolute predictive value. As target phenotypes, we extracted CVD and MDD 729 cases according to healthcare registry ICD codes from data field 41270 (see Supplementary Table 12). 730 We used logistic regression analysis to predict case status from each PRS while controlling for the first 731 10 principal components for ancestry, sex, and year of birth. Continuous variables were standardized 732 and centered. We estimated Nagelkerke's  $R^2$  to capture explained variance in the disease traits.

# 733 Tissue and cell-type analysis

To gain insight into the biological mechanisms underlying the common liability to MDD and ASCVD,
we performed a tissue and cell-type analysis using partitioned LDSC. Cell-type identification was based
on the top decile of specifically expressed genes (referred to as top decile expression proportion [TDEP]
genes). The methodology has been described extensively in previous studies<sup>69-71</sup>.

738

We identified TDEP genes for brain cell-types from single-nucleus RNA-seq data measured in dissections of three adult human post-mortem brain samples for the Adult Human Brain Atlas<sup>28</sup>, part of the Human Cell Atlas. We used the manually annotated 31 superclusters and 461 clusters provided by the atlas<sup>28</sup>. We considered a curated set of 18,090 protein-coding autosomal genes, excluding those in the *HLA* region (because the method relies on LDSC), with expression in at least one of the 461 cellclusters.

745

To establish TDEP genes for 16 human tissues, we utilized bulk RNA-seq data from GTEx  $v8^{72}$ . In

- 747 line with previous research, we removed tissues with <100 donors and non-natural tissues (e.g., cell
- <sup>748</sup> lines) as well as testis tissues (expression outlier)<sup>69.</sup> Prior to analysis in partitioned LDSC, we expanded
- the boundaries of TDEP genes by 100kb to include possible enhancers or promoters.
- 750

751 We tested the associations between GWAS traits and tissue/cell-types by investigating heritability

752 enrichment within the TDEP genes for each tissue/cell-type. To ensure that annotation enrichment could

753 not be better explained by other overlapping annotations, we adjusted for enrichment in 53 previously

754 defined baseline LDSC annotations (LDSC v1.0.1) of coding, UTR, promoter, intronic, various

enhancers, histone marks and other epigenetic marks, genomic regions<sup>71</sup>. 755

#### 756 Pathways of association between MDD and CVD

#### 757 Mediation in Genomic SEM

758 We employed several different techniques to assess whether the association between MDD and CVD 759 could be explained by shared risk factors. First, we estimated the genome-wide genetic correlations 760 adjusting for the effects of risk factors using Genomic SEM. To aid interpretation, we added the 761 covariates in groups, controlling for all trait groups separately (psychosocial/lifestyle, childhood 762 maltreatment, metabolic, or inflammation traits; see Supplementary Table 1). We only included traits 763 in the covariate groups that showed significant genome-wide genetic correlation with MDD. Note that 764 we did not adjust for blood pressure traits, since none of the blood pressure traits showed genome-wide 765 significant correlation with MDD. Attenuation of genetic correlation after adjustment was taken to indicate that shared risk factors account for some (or all) of the association between MDD and CVD. 766

767

Next, we modeled the risk factors explicitly as mediators in Genomic SEM. If the direct effect is 768 769 attenuated in the mediation model as compared to the covariate model, we view this as tentative support 770 for the existence of mediation (following procedures suggested by the software developers<sup>73</sup>). Note 771 however that this interpretation relies on untestable assumptions. Finally, we also tested the effects of 772 individual risk factors (both as covariates and mediators) instead of grouping them.

773 Univariable and multivariable Mendelian randomization

774 To test if the associations between MDD and CVD and risk factors were causal, we used Mendelian 775 Randomization (MR). We assessed the effects of MDD on the CVDs and risk factors, the effect of the 776 CVDs and risk factors on MDD, and the effect of latent MDD-ASCVD on risk factors. MR uses genetic 777 variants as instrumental variables to assess the presence of causal effects of an 'exposure' on an 778 'outcome'. Core assumptions include that the instrumental variables are robustly associated with 779 exposure and are not associated with the outcome (other than through the effect from exposure) or 780 unmeasured confounders. We used the inverse variance weighted (IVW) estimate in the two-sample 781 MR R-package<sup>74</sup> as our main estimate. As instrument SNPs, we selected independent GWAS hits at 782  $P < 5 \times 10^{-8}$ ,  $R^2 < 0.001$ , and distance <5Mb. In the analysis of the effect of genetic instruments of 783 peripheral artery disease, physical activity, childhood maltreatment, and IL6 on MDD risk, we allowed 784 instruments with higher P-values to be able to reach a total of 10 instruments (P < 1e-5). For the MDD-ASCVD exposure, we used SNPs that showed no significantly heterogenous effects in the Genomic 785 786 SEM model ( $Q_{pval}$ ).05, see above), in order to limit the possibility of pleiotropic effects of this, by 787 nature, heterogenous instrument.

788

789 We performed several sensitivity analyses to test and adjust for violation of MR assumptions. All 790 analyses were Steiger filtered, meaning that all SNPs that explained significantly more variance in the outcome than the exposure were excluded as instruments<sup>75</sup>. Weighted median and mode regression were 791 used to correct for effect size outliers that could represent pleiotropic effects<sup>76</sup>. MR-Egger regression 792 793 was used to assess pleiotropy (pleiotropy leads to a significant intercept) and correct for it (unless  $I^2$ 794 indicated NOME violation of the NO Measurement Error [NOME] assumption, in which case we did not report MR-Egger results 77,78). Second, to assess the strength of our instruments, we used Cochran's 795

Q to assess heterogeneity in the SNP effects<sup>79</sup> and the F-statistic to control for weak instrument bias<sup>80</sup>. 796

797 Third, we performed sensitivity analyses to gauge the effect of sample overlap in the GWASs that were 798 used. Although sample overlap has been suggested to not greatly impact MR results when the source 799 GWASs have a large sample size and the overlap is limited<sup>81</sup>, we wanted to ensure sample overlap did not lead to bias in our findings. We assessed the genetic covariance intercepts for all MDD-trait pairs 800 from the LDSC analyses and observed that most were more than 1 SD away from 0, indicating that 801 sample overlap was present (Supplementary Table 2). We repeated the analyses with MDD summary 802 803 statistics leaving out the UKB sample, which is the sample responsible for most of the overlap and 804 compared the results. Also, we repeated the analyses using Latent Heritable Confounder MR (LHC-805  $MR^{31}$ ), which aims to correct for the presence of unmeasured heritable confounders as well as sample 806 overlap.

807

808 Subsequently, we test the adjusted pathways using multivariable MR (MVMR) analyses. The difference 809 with the mediation test in Genomic SEM is that we now use instrumental variables that corroborate a 810 causal interpretation. Because MVMR relies on simple regression analysis, it cannot formally test 811 mediation; instead, the causal estimate is adjusted for the risk factor. To support a directional interpretation, we included only risk factors as mediators that were significantly affected by MDD 812 813 according to the univariable analysis results. In MVMR, only an IVW estimate can be derived. Steiger 814 filtering was performed on the exposure-outcome association. These analyses were not replicated in 815 LHC, which does not accommodate multivariable analyses. For ease of interpretation, we again grouped the mediators and adjusted for all mediators in a group concurrently. We only included a mediator in a 816 817 group if it was significant in the univariate analysis. Additionally, we performed analyses adjusting for single mediators. We selected instruments for each variable in a model by a clumping step with the 818 819 same parameters as in the univariate MR case ( $P < 5 \times 10^{-8}$ ,  $R^2 < 0.001$ ). We then combined instruments 820 for all variables in a model into a single set of instruments and performed another clumping step with 821 the same parameters. These instruments were then aligned to the same effect allele. We estimated the 822 effect of genetic liability to MDD on CVD traits adjusting for covariates using multivariate MR with the MVMR R-package<sup>82</sup>. 823

### **Data availability** 824

Links to download publicly available published GWAS summary statistics data used as inputs in this 825 study are listed in Supplementary Table 1. Single nucleus RNA sequencing data in the adult human 826 827 brain can be found at https://github.com/linnarsson-lab/adult-human-brain. Researchers can request access to the UK-Biobank data resources at https://www.ukbiobank.ac.uk/enable-your-research/apply-828 for-access; data for PRS analysis described in this study were accessed under accession number 22224. 829 830 Gene expression data from human tissues can be found at https://www.gtexportal.org/home/datasets. 831 Summary statistics for MDDCVD are available upon request.

### **Code availability** 832

833 Code used for processing and analyzing data in this work will be uploaded to https://github.com/jacobbergstedt. 834 Code for singularity containers can be found at https://github.com/comorment. 835

# **References**

- 836 1. Han, X. et al. Disease trajectories and mortality among individuals diagnosed with depression: a 837 community-based cohort study in UK Biobank. Mol Psychiatry 26, 6736–6746 (2021).
- 2. Nemeroff, C. B. & Goldschmidt-Clermont, P. J. Heartache and heartbreak-the link between 838 839 depression and cardiovascular disease. Nat Rev Cardiol 9, 526-539 (2012).
- 840 Kendler, K. S., Gardner, C. O., Fiske, A. & Gatz, M. Major Depression and Coronary Artery 3. 841 Disease in the Swedish Twin Registry. Arch Gen Psychiatry 66, 857 (2009).
- Xian, H. et al. Genetic vulnerability and phenotypic expression of depression and risk for ischemic 842 4. 843 heart disease in the Vietnam era twin study of aging. Psychosom Med 72, 370-5 (2010).
- 844 5. Zhang, F., Cao, H. & Baranova, A. Shared Genetic Liability and Causal Associations Between Major Depressive Disorder and Cardiovascular Diseases. Front Cardiovasc Med 8, (2021). 845
- Als, T. D. et al. Depression pathophysiology, risk prediction of recurrence and comorbid 846 6. psychiatric disorders using genome-wide analyses. Nat Med 29, 1832–1844 (2023). 847
- Ravnor, D. A., Pogue-Geile, M. F., Kamarck, T. W., McCaffery, J. M. & Manuck, S. B. 848 7. 849 Covariation of Psychosocial Characteristics Associated With Cardiovascular Disease: Genetic and Environmental Influences. Psychosom Med 64, 191–203 (2002). 850
- 851 8. Vaccarino, V. et al. Depression and coronary heart disease: 2018 position paper of the ESC 852 working group on coronary pathophysiology and microcirculation. Eur Heart J 41, 1687–1696 853 (2020).
- 9. Penninx, B. W. J. H. Depression and cardiovascular disease: Epidemiological evidence on their 854 855 linking mechanisms. Neurosci Biobehav Rev 74, 277–286 (2017).
- 856 10. Roth, G. A. et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol 76, 2982–3021 (2020). 857
- Fan, M. et al. Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a 858 11. 859 prospective study of 385 292 UK biobank participants. Eur Heart J 41, 1182-1189 (2020).
- 860 12. Valtorta, N. K., Kanaan, M., Gilbody, S., Ronzi, S. & Hanratty, B. Loneliness and social isolation as risk factors for coronary heart disease and stroke: systematic review and meta-analysis of 861 longitudinal observational studies. Heart 102, 1009-16 (2016). 862
- 13. Suglia, S. F. et al. Childhood and Adolescent Adversity and Cardiometabolic Outcomes: A 863 864 Scientific Statement From the American Heart Association. Circulation 137, (2018).
- 14. 865 Schultz, W. M. et al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation 137, 2166–2178 (2018). 866
- Libby, P. et al. Atherosclerosis. Nat Rev Dis Primers 5, 56 (2019). 867 15.
- 868 16. Libby, P. et al. Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic 869 of the Week. J Am Coll Cardiol 72, 2071–2081 (2018).
- 870 Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary 17. 871 imperative to modern treatment target. Nat Rev Immunol 16, 22-34 (2016).
- 872 Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary 18. 873 imperative to modern treatment target. Nat Rev Immunol 16, 22-34 (2016).
- 19. Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B. & Khandaker, G. M. Prevalence of low-grade 874 875 inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med 876 49, 1958–1970 (2019).
- 877 20. Suneson, K., Lindahl, J., Chamli Hårsmar, S., Söderberg, G. & Lindqvist, D. Inflammatory 878 Depression-Mechanisms and Non-Pharmacological Interventions. Int J Mol Sci 22, (2021).
- 879 21. Carney, R. M. & Freedland, K. E. Depression and coronary heart disease. Nat Rev Cardiol 14, 880 145-155 (2017).

- 881 22. Lu, Y., Wang, Z., Georgakis, M. K., Lin, H. & Zheng, L. Genetic Liability to Depression and Risk 882 of Coronary Artery Disease, Myocardial Infarction, and Other Cardiovascular Outcomes. J Am 883 Heart Assoc 10, (2021).
- 884 Li, G. H.-Y. et al. Evaluation of bi-directional causal association between depression and 23. cardiovascular diseases: a Mendelian randomization study. Psychol Med 52, 1765–1776 (2022). 885
- 24. Hare, D. L., Toukhsati, S. R., Johansson, P. & Jaarsma, T. Depression and cardiovascular disease: 886 887 a clinical review. Eur Heart J 35, 1365-1372 (2014).
- 888 25. Frei, O. et al. Bivariate causal mixture model quantifies polygenic overlap between complex traits 889 beyond genetic correlation. Nat Commun 10, 2417 (2019).
- 890 26. Werme, J., van der Sluis, S., Posthuma, D. & de Leeuw, C. A. An integrated framework for local 891 genetic correlation analysis. Nat Genet 54, 274–282 (2022).
- Grotzinger, A. D. et al. Genomic SEM Provides Insights into the Multivariate Genetic 892 27. 893 Architecture of Complex Traits. Nat Hum Behav 305029 (2018).
- 894 28. Siletti, K. et al. Transcriptomic diversity of cell types across the adult human brain. Science (1979) 895 382. (2023).
- 896 29. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in 897 genome-wide association studies. Nat Genet 47, 291 (2015).
- 898 30. Zeng, J. et al. Signatures of negative selection in the genetic architecture of human complex traits. 899 Nat Genet 50, 746–753 (2018).
- 900 31. Darrous, L., Mounier, N. & Kutalik, Z. Simultaneous estimation of bi-directional causal effects 901 and heritable confounding from **GWAS** summary statistics. (2020)doi:10.1101/2020.01.27.20018929. 902
- 903 32. Zhang, F., Cao, H. & Baranova, A. Shared Genetic Liability and Causal Associations Between 904 Major Depressive Disorder and Cardiovascular Diseases. Front Cardiovasc Med 8, (2021).
- 905 Li, G. H.-Y. et al. Evaluation of bi-directional causal association between depression and 33. 906 cardiovascular diseases: a Mendelian randomization study. Psychol Med 52, 1765–1776 (2022).
- 907 34. Torgersen, K. et al. Shared genetic loci between depression and cardiometabolic traits, PLoS 908 Genet 18, e1010161 (2022).
- 909 35. Hagenaars, S. P. et al. Genetic comorbidity between major depression and cardio-metabolic traits, 910 stratified by age at onset of major depression. American Journal of Medical Genetics Part B: 911 Neuropsychiatric Genetics 183, 309–330 (2020).
- 912 36. Wei, H.-L. et al. Disrupted resting-state functional connectivity of the thalamus in patients with 913 coronary heart disease. Helivon 9, e13423 (2023).
- 914 37. Rosen, S. D. Silent Ischemia as a Central Problem: Regional Brain Activation Compared in Silent and Painful Myocardial Ischemia. Ann Intern Med 124, 939 (1996). 915
- 916 38. Rosen, S. D. et al. Central nervous pathways mediating angina pectoris. The Lancet 344, 147–150 917 (1994).
- 918 39. Greicius, M. D. et al. Resting-State Functional Connectivity in Major Depression: Abnormally Increased Contributions from Subgenual Cingulate Cortex and Thalamus. Biol Psychiatry 62, 919 920 429-437 (2007).
- 921 40. Paul, E. R., Östman, L., Heilig, M., Mayberg, H. S. & Hamilton, J. P. Towards a multilevel model 922 of major depression: genes, immuno-metabolic function, and cortico-striatal signaling. Transl 923 Psychiatry 13, 171 (2023).
- 924 41. Zhao, B. et al. Heart-brain connections: Phenotypic and genetic insights from magnetic resonance 925 images. Science 380, abn6598 (2023).
- 926 42. Torgersen, K. et al. Shared genetic loci between depression and cardiometabolic traits. PLoS 927 Genet 18, e1010161 (2022).

- 928 43. Milaneschi, Y., Lamers, F., Berk, M. & Penninx, B. W. J. H. Depression Heterogeneity and Its 929 Biological Underpinnings: Toward Immunometabolic Depression. Biol Psychiatry 88, 369–380 930 (2020).
- 931 44. Dashti, H. S. et al. Genome-wide association study identifies genetic loci for self-reported habitual 932 sleep duration supported by accelerometer-derived estimates. Nat Commun 10, 1100 (2019).
- 933 45. Shen, O. et al. Psychiatric disorders and subsequent risk of cardiovascular disease: a longitudinal 934 matched cohort study across three countries. *EClinicalMedicine* **61**, 102063 (2023).
- 935 46. Tang, B., Yuan, S., Xiong, Y., He, Q. & Larsson, S. C. Major depressive disorder and 936 cardiometabolic diseases: a bidirectional Mendelian randomisation study. Diabetologia 63, 1305-937 1311 (2020).
- 938 47. Lu, Y., Wang, Z., Georgakis, M. K., Lin, H. & Zheng, L. Genetic Liability to Depression and Risk 939 of Coronary Artery Disease, Myocardial Infarction, and Other Cardiovascular Outcomes. J Am 940 Heart Assoc 10, (2021).
- 941 48. Shah, S. et al. Genome-wide association and Mendelian randomisation analysis provide insights 942 into the pathogenesis of heart failure. Nat Commun 11, 163 (2020).
- 943 49. Fry, A. et al. Comparison of Sociodemographic and Health-Related Characteristics of UK 944 Biobank Participants With Those of the General Population. Am J Epidemiol 186, 1026–1034 945 (2017).
- 946 50. Morris, T. T. et al. Interpretation of Mendelian randomization using a single measure of an 947 exposure that varies over time. Int J Epidemiol 51, 1899–1909 (2022).
- 948 Taylor, W. D., Aizenstein, H. J. & Alexopoulos, G. S. The vascular depression hypothesis: 51. 949 mechanisms linking vascular disease with depression. Mol Psychiatry 18, 963–74 (2013).
- 950 52. Kappelmann, N. et al. Dissecting the Association Between Inflammation, Metabolic 951 Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample 952 Mendelian Randomization Study. JAMA Psychiatry 78, 161–170 (2021).
- 953 53. Khandaker, G. M. et al. Shared mechanisms between coronary heart disease and depression: 954 findings from a large UK general population-based cohort. Mol Psychiatry 25, 1477–1486 (2020).
- Wootton, R. E. et al. Evidence for causal effects of lifetime smoking on risk for depression and 955 54. 956 schizophrenia: a Mendelian randomisation study. Psychol Med 50, 2435–2443 (2020).
- 957 55. Behrooz, L., Abumoawad, A., Rizvi, S. H. M. & Hamburg, N. M. A modern day perspective on 958 smoking in peripheral artery disease. Front Cardiovasc Med 10, 1154708 (2023).
- 959 56. Office of the Surgeon General (OSG). Our Epidemic of Loneliness and Isolation: The U.S. 960 Surgeon General's Advisory on the Healing Effects of Social Connection and Community. (2023).
- 961 57. Ernst, M. et al. Loneliness before and during the COVID-19 pandemic: A systematic review with 962 meta-analysis. American Psychologist 77, 660-677 (2022).
- 963 González, H. M. & Tarraf, W. Comorbid cardiovascular disease and major depression among 58. ethnic and racial groups in the United States. Int Psychogeriatr 25, 833-841 (2013). 964
- Watkins, D. C., Assari, S. & Johnson-Lawrence, V. Race and Ethnic Group Differences in 965 59. 966 Comorbid Major Depressive Disorder, Generalized Anxiety Disorder, and Chronic Medical Conditions. J Racial Ethn Health Disparities 2, 385–394 (2015). 967
- 968 60. Felger, J. C. & Miller, A. H. Identifying Immunophenotypes of Inflammation in Depression: 969 Dismantling the Monolith. Biol Psychiatry 88, 136–138 (2020).
- 970 61. Kappelmann, N. et al. Dissecting the Association Between Inflammation, Metabolic 971 Dysregulation, and Specific Depressive Symptoms. JAMA Psychiatry 78, 161 (2021).
- 972 62. Howrigan, D. P. Nealelab/UK Biobank GWAS: et al. v2. (2023)973 doi:10.5281/ZENODO.8011558.
- 974 Doherty, A. et al. GWAS identifies 14 loci for device-measured physical activity and sleep 63. 975 duration. Nat Commun 9, 5257 (2018).

- 976 64. Akdeniz, B. C. *et al.* COGEDAP: A COmprehensive GEnomic Data Analysis Platform. *arXiv:*977 2212.14103 (2022).
- 65. Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score regression
  b) that maximizes the potential of summary level GWAS data for SNP heritability and genetic
  c) correlation analysis. *Bioinformatics* 33, 272–279 (2017).
- 66. Hindley, G. *et al.* Charting the Landscape of Genetic Overlap Between Mental Disorders and
  Related Traits Beyond Genetic Correlation. *Am J Psychiatry* **179**, 833–843 (2022).
- Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
  annotation of genetic associations with FUMA. *Nat Commun* 8, 1826 (2017).
- 985 68. Wang, D. *et al.* Comprehensive functional genomic resource and integrative model for the human
  986 brain. *Science (1979)* 362, (2018).
- Bryois, J. *et al.* Genetic identification of cell types underlying brain complex traits yields insights
  into the etiology of Parkinson's disease. *Nat Genet* 52, 482–493 (2020).
- 989 70. Skene, N. G. *et al.* Genetic identification of brain cell types underlying schizophrenia. *Nat Genet*990 50, 825–833 (2018).
- Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
  association summary statistics. *Nat Genet* 47, 1228–1235 (2015).
- Aguet, F. *et al.* The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science (1979)* 369, 1318–1330 (2020).
- 99573.Nivard,M.MediationmodelinGenomicSEM.996https://gist.github.com/MichelNivard/04bf4ddcf3c32f905175de3058ca967a (2018).
- 997 74. Hemani, G., Bowden, J. & Davey Smith, G. Evaluating the potential role of pleiotropy in
  998 Mendelian randomization studies. *Hum Mol Genet* 27, R195–R208 (2018).
- 999 75. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between imprecisely
  1000 measured traits using GWAS summary data. *PLoS Genet* 13, e1007081 (2017).
- 100176.Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data Mendelian1002randomization via the zero modal pleiotropy assumption. Int J Epidemiol 46, 1985–1998 (2017).
- 1003 77. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments:
  1004 effect estimation and bias detection through Egger regression. *Int J Epidemiol* 44, 512–525 (2015).
- 1005 78. Bowden, J. *et al.* Assessing the suitability of summary data for two-sample Mendelian
  1006 randomization analyses using MR-Egger regression: the role of the I2 statistic. *Int J Epidemiol* 45, 1961–1974 (2016).
- 1008 79. Bowden, J., Hemani, G. & Davey Smith, G. Invited Commentary: Detecting Individual and Global
  1009 Horizontal Pleiotropy in Mendelian Randomization—A Job for the Humble Heterogeneity
  1010 Statistic? *Am J Epidemiol* 187, 2681–2685 (2018).
- 101180.Burgess, S. & Thompson, S. G. Avoiding bias from weak instruments in Mendelian randomization1012studies. Int J Epidemiol 40, 755–764 (2011).
- 101381.Mounier, N. & Kutalik, Z. Bias correction for inverse variance weighting Mendelian1014randomization. Genet Epidemiol 47, 314–331 (2023).
- 101582.Sanderson, E., Spiller, W. & Bowden, J. Testing and correcting for weak and pleiotropic1016instruments in two-sample multivariable Mendelian randomization. Stat Med 40, 5434–54521017(2021).
- 1018
- 1019

#### **Acknowledgments** 1020

1021 This work was supported by European Union's Horizon 2020 Research and Innovation Programme (CoMorMent project; Grant #847776). JAP was supported by the the US National Institutes of Mental Health 1022 1023 (R01MH123724). NP was supported by the Marie Skłodowska-Curie Actions Grant 801133 (Scientia 1024 fellowship) and RCN 300309. JLT is supported by a European Research Council (ERC) Starting grant (UNRAVEL-CAUSALITY, grant number 101076686) and by Foundation Volksbond Rotterdam. CML is 1025 part-funded the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS 1026 1027 Foundation Trust and King's College London. AMM is supported by the Wellcome Trust (220857/Z/20/Z) 1028 and UKRI (MR/W014386/1). ADB was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), the EU H2020 Program (Grant No. 667302, "CoCA"), NIH/NIMH 1029 (1R01MH124851-01). OA was supported by the European Union's Horizon 2020 research and innovation 1030 program (grant agreement No 847776 and 964874), Research Council of Norway (223273, 296030, 326813). 1031 PFS gratefully acknowledges support from the Swedish Research Council (Vetenskapsrådet, award 1032 1033 D0886501), the US National Institutes of Mental Health (R01s MH124871, MH121545, and MH123724), and the Horizon 2020 Programme of the European Union (grant agreement No 847776). LY was supported 1034 1035 by the European Research Council (grant agreement ID 101042183). The authors acknowledge HERMES 1036 and CARDIoGRAMplusC4D consortia for contributing data and guidance. The PRS analyses have been conducted using the UK-Biobank Resource under Application Number 22224. They were enabled by 1037 resources in project sens2017519 provided by the National Academic Infrastructure for Supercomputing in 1038 1039 Sweden (NAISS) at UPPMAX, funded by the Swedish Research Council through grant agreement no. 2022-1040 06725. This work was performed on Services for Sensitive Data, University of Oslo, with resources provided by UNINETT Sigma2, the national infrastructure for high performance computing and data storage in 1041 Norway. 1042

### **Author contributions** 1043

1044 This study was conceived by JB, PFS, YL, and FF. It was supervised by YL and FF. JB, JAP, and ZM were 1045 responsible for the main analyses, visualization, and the drafting of the manuscript. AH performed the tissue expression analyses with help and supervision from SY, JHL, and PFS, who also helped with the writing 1046 and interpretation of these results. NP was involved in providing and cleaning GWAS summary statistic 1047 data. DJAS supervised the Genomic SEM analysis and JLT the MR analyses. OF and AS were involved in 1048 1049 providing the containerized software used in this project and supervising the MiXeR analyses, JJM, OS, SH, 1050 PT, AB, and TW contributed to interpreting findings. CML, AMM, TDA, and ADB were responsible for 1051 the MDD GWAS summary statistics and were involved in the interpretation of findings. SH helped with 1052 UKB data access and curation for the PRS analyses. SH, UVA, OA, PFS, YL and FF provided suggestions and expert supervision and contributed to the writing. All authors have read and provided feedback on the 1053 manuscript. 1054

### **Competing interests** 1055

1056 CML sits on the SAB of Myriad Neuroscience and has received speaker/consultancy fees from SYNLAB 1057 and UCB. OAA is a consultant to Cortechs.ai, and has received speaker's honoraria from Lundbeck, Janssen 1058 and Sunovion. PFS has received consulting fees from and is a shareholder of Neumora therapeutics. Other 1059 authors declare no competing interests.



## 1061 1062

## Extended Data Fig. 1 | Genetic correlation of MDD and MDD symptoms with CVDs.

(a) Results are based on LD Score Regression analysis. Points and error bars represent genetic correlation and 95% CIs. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1. (b) Local genetic correlation between MDD and CVDs in 16 loci in the HLA region. Only loci with marginally significant local heritability for both traits are shown. Points above the vertical line are significant based on multiple testing adjustment for considered loci performed for each CVD trait separately.

MDD=Major Depressive Disorder; AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease





### 1064 Extended Data Fig. 2 | Genetic correlation and polygenicity for MDD, CVD, and risk factors.

- 1065 (a) Heatmap of the genetic correlations between MDD, the CVDs, and the risk factors, with the color indicating the 1066 effect direction (negative: red, positive: blue) and the size and shade of the square illustrating the size of the 1067 correlation. Results are based on LD Score Regression analysis. (b) Estimates of number of non-zero variants for 1068 from SBayesS for each trait (y-axis) and estimates of non-zero variants required to explain 90% of trait heritability 1069 for each trait from MiXeR (x-axis) for MDD, the CVDs, and the risk factors. Note that for PAD polygenicity 1070
- estimates did not converge for SBayeS, possibly because of few number of cases.
- 1071 MDD=Major Depressive Disorder; AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery
- 1072 Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical
- activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-1073 High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein
- 1074 1075
- 1076
- 1077



1078 Extended Data Fig. 3 | Common latent factor underlying atherosclerotic CVD.

(a) Latent atherosclerotic CVD (ASCVD) model, defined by stroke, peripheral artery disease (PAD), heart failure (HF), and coronary artery disease (CAD). All 'observed' traits are based on GWAS summary statistics. Results are from confirmatory factor analysis in Genomic SEM, and standardized factor loadings are given for each path. Circular dashed arrows give the trait variance. (b) Manhattan plot of the GWAS on ASCVD, with each dot representing a SNP with its position on the x-axis and its P-value on the y-axis. Genome-wide significant SNPs with a significant heterogeneity  $Q_{SNP}$  (with a strong effect on one or some of the indicators that was not well explained through the common latent factor) are displayed in grey. The dashed line indicates the genome-wide significance threshold (P<5e-8).



1079

### 1080 Extended Data Fig. 4 | The genomic signature of MDD-ASCVD.

1081 (a) Enrichment for the MDD-ASCVD GWAS SNPs in genome-wide significant SNPs for traits in the GWAS catalog 1082 computed using FUMA. The traits are as reported in the original study. Note that sleep duration here is a 1083 dichotomization of self-reported sleep. Full name in GWAS catalog of the trait "Coronary artery disease\*" is 1084 "Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery 1085 bypass grafting, angina or chromic ischemic heart disease)". The dashed black line indicates the significance 1086 threshold after Benjamini-Hochberg adjustment. Adjustment for multiple testing was conducted over all traits in the 1087 GWAS catalog (>3500 traits). (b) The five SNPs that were significantly associated with MDD-ASCVD, but not with 1088 any of the constituent traits, with their P-value in the GWAS of the constituent traits. The dashed line indicates the 1089 genome-wide significance threshold (P<5e-8). (c) Genetic correlation of PHQ-9 MDD symptoms with MDD, and 1090 MDD-ASCVD, with bars representing 95% confidence intervals. Results are based on LD Score Regression analysis. 1091 (d) Genetic correlation of MDD, MDD-ASCVD, and ASCVD with five psychiatric disorders, with bars representing 1092 95% confidence intervals. Results are based on LD Score Regression analysis.

- 1093
- ADHD = Attention Deficit and Hyperactivity Disorder; PTSD = Posttraumatic Stress Disorder. 1094
- 1095



## Extended Data Fig. 5 | Genetic correlation between CVD and risk factors

Results are based on LD Score Regression analysis. Points and error bars represent correlations and 95% CIs. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1. Open dots indicate a non-significant genetic correlation.

AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein





## 1097

# Extended Data Fig. 6 | Genetic correlation between MDD traits and risk factors

Results are based on LD Score Regression analysis. Points and error bars represent correlations and 95% CIs. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1. Open dots indicate a non-significant genetic correlation.

MDD=Major Depressive Disorder; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein



1098

# Extended Data Fig 7 | Local genetic correlations between MDD and risk factors.

Volcano plots based on LAVA results. Local genetic correlation between MDD and each of the risk factors (x-axis) and the corresponding -log10 transformed P-value (y-axis). Correlations were estimated in the loci that showed marginally significant local heritability in 2,495 considered genomic regions. Loci exceeding the horizontal line are significant at P<sub>FDR</sub><.05. Multiple testing was adjusted for individually for each trait over considered loci. Psychosocial=Psychosocial/Lifestyle; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein





## 1099

Extended Data Fig. 8 | Genetic correlation between MDD and CVD when adjusting for individual risk factors Results from Genomic SEM. Bars represent 95% confidence intervals. Reference estimates of the association without any adjustment are printed in black.

AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein

1100



## Extended Data Fig. 9 | Assessment of evidence for causal associations between MDD, CVD, and risk factors.

Results from univariable and multivariable Mendelian randomization (MR) analysis (Inverse variance weighted estimates are shown) (a) Effect of liability to MDD (exposure) on CVD and risk factors (outcomes) after excluding the UKB sample from MDD (which was responsible for most of the sample overlap in the exposure and outcome GWAS summary statistics). (b) Estimated fffect of CVD and risk factors on MDD after excluding the UKB. (c) Results from LHC-MR, that corrects for heritable confounders and sample overlap, with the standard inverse variance weighted MR estimate given as reference, for the effect of MDD on CVD and risk factors. (d) Effect of liability to MDD-ASCVD on outcomes and risk factors. A-c Statistically significant pleiotropic estimates are indicated with a red asterisk. The term beta refers to the log odds ratio.

Psychosocial=Psychosocial/Lifestyle; AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein



## 1104

Extended Data Fig. 10 | Effects of liability to MDD on CVDs when adjusting for individual risk factors

Results from multivariable Mendelian randomization. Bars represent 95% confidence intervals. Reference estimates of the association without any adjustment are printed in black.

AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein